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Given the survival benefits of adjuvant chemotherapy for advanced ovarian cancer (OC), we examined the associations of survival
with the time interval from debulking surgery to initiation of chemotherapy and with the duration of chemotherapy. Among patients
X65 years with stages III/IV OC diagnosed between 1991 and 2002 in the Surveillance, Epidemiology, and End Results-Medicare
database, we developed regression models of predictors of the time interval from surgery to initiation of chemotherapy and of the
total duration of chemotherapy. Survival was examined with Cox proportional hazards models. Among 2558 patients, 1712 (67%)
initiated chemotherapy within 6 weeks of debulking surgery, while 846 (33%) began treatment 46 weeks. Older age, black race,
being unmarried, and increased comorbidities were associated with delayed initiation of chemotherapy. Delay of chemotherapy was
associated with an increase in mortality (hazard ratio (HR)¼1.11; 95% CI, 1.0–1.2). Among 1932 patients in the duration of
treatment analysis, the 1218 (63%) treated for 3–7 months had better survival than the 714 (37%) treated for p3 months
(HR¼0.84; 95% CI, 0.75–0.94). This analysis represents one of the few studies describing treatment delivery and outcome in
women with advanced OC. Delayed initiation and early discontinuation of chemotherapy were common and associated with
increased mortality.
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Over the past three decades, advances in chemotherapy, including
platinum- and taxane-based regimens and intraperitoneal chemo-
therapy, have improved survival among women with advanced
ovarian cancer (OC) (Alberts et al, 1996; Markman et al, 2001;
Armstrong et al, 2006).
Failure to receive standard therapy is associated with decreased
survival (Tingulstad et al, 2003). However, not all patients,
especially elderly patients, are offered optimal chemotherapy.
A study by our group found that although 83% of elderly
patients with stage III and IV disease received some form of
chemotherapy, only 52% received platinum-based therapy. Factors
associated with non-platinum-based treatment included older age,
nonwhite ethnicity and number of comorbid medical conditions
(Sundararajan et al, 2002). Provider type and surgical volume have
also been shown to influence the likelihood of receiving
chemotherapy (Schrag et al, 2006).
Dose-intense treatment (higher mg per m
2 per unit of time) has
been found to improve the survival of patients with breast cancer
and other cancers (Hudis et al, 1999; Citron et al, 2003). But most
clinical trials among patients with OC have failed to show a
survival advantage of dose-intense regimens (McGuire et al, 1995,
1996; Conte et al, 1996; Jakobsen et al, 1997; McGuire, 1997; Gore
et al, 1998). For example, the Gynecologic Oncology Group (GOG)
compared patients treated with eight cycles of standard dose
cisplatin and cyclophosphamide to those receiving four cycles of
high-dose therapy. Although response rates and survival were
similar, toxicity was more common in the dose-intense group than
in the standard dose group (McGuire et al, 1995).
The optimal timing of chemotherapy initiation in the post-
operative period and the ideal duration of treatment (including
number of cycles) have not been determined. However, in most
clinical trials, patients are required to register within 6 weeks of
surgery. Studies examining the time from surgery to initiation of
adjuvant chemotherapy have reported varied results; however,
some have suggested that prolonging the interval between surgery
and the initiation of adjuvant chemotherapy adversely affects
survival (Omura et al, 1989; Warwick et al, 1995; Flynn et al, 2002;
Gadducci et al, 2005; Paulsen et al, 2006a; Aletti et al, 2007).
The goal of our study was to analyse the association
of demographic and clinical factors with delay in initiation of
chemotherapy and early termination of chemotherapy in women
Received 17 December 2007; revised 14 February 2008; accepted 21
February 2008; published online 18 March 2008
*Correspondence: Dr D Hershman, Department of Medicine, Herbert
Irving Comprehensive Cancer Center, College of Physicians and
Surgeons, 161 Ft Washington Room 1068, New York, NY 10032,
USA; E-mail: dlh23@columbia.edu
British Journal of Cancer (2008) 98, 1197–1203
& 2008 Cancer Research UK All rights reserved 0007– 0920/08 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
swith advanced OC and to evaluate the association of those aspects
of treatment with survival.
MATERIALS AND METHODS
Data source
For this analysis, we obtained data from two linked databases. The
National Cancer Institute’s Surveillance, Epidemiology, and End
Results (SEER) cancer registry collects data on cancer patients
representing 26% of the US population from five state-based and
seven county-based cancer registries. The SEER database includes
patient demographics; cancer organ/site, histology, stage and other
clinical markers; and primary treatment. The Center for Medicare
and Medicaid Services (CMS) maintains a database of patients on
Medicare with diagnosis codes and procedural billing codes for
their medical expenses. The SEER-Medicare linked database,
initiated in 1991, has been previously described and validated
(Klabunde et al, 2000; Warren et al, 2002).
Patient selection criteria
Eligible patients were those 65 years of age or older at diagnosis
with a first primary epithelial OC, American Joint Cancer
Committee (AJCC) stage III or IV, and diagnosed between 1
January 1991 and 31 December 2002.
Patients were included in the analysis if they received at least
one cycle of chemotherapy within 12 months after surgical
resection, survived for at least 7 months after initiating
chemotherapy and received chemotherapy continuously for p7
months. Patients who received chemotherapy for 47 months may
have had refractory disease, which is not the focus of this study.
Patients who did not receive primary, cancer-directed surgery at
all or prior to receiving chemotherapy were excluded. Patients who
were members of a Medicare health maintenance organization
(HMO) at any time from 12 months before to 8 months after their
diagnosis of OC also were excluded, because HMOs do not report
claims for individual expenses to Medicare. Other exclusion
criteria were gaps in Medicare Part A or B coverage during the
study period, histologically unconfirmed diagnosis, non-epithelial
tumour histology and tumour of low malignant potential. Among
3585 patients who underwent surgery for OC, 1021 did not receive
chemotherapy within 12 months of surgery and were excluded.
For each eligible patient, we obtained data on age group at
diagnosis, year of diagnosis, race/ethnicity, marital status, tumour
stage (III or IV), tumour histology (serous, mucinous, endome-
trioid, other), comorbidity score, residence (metropolitan or non-
metropolitan), type of hospital (teaching or non-teaching) in
which they were diagnosed, and socioeconomic indicators for their
census tract/zip code of residence from SEER. Comorbidity data
and treatment data were obtained from Medicare.
Treatment delay
The time, in weeks, from surgical resection until delivery of the
first cycle of chemotherapy was calculated for each patient. Based
on the inclusion criteria for GOG clinical trials, we categorised
patients who initiated chemotherapy p6 weeks after surgical
resection as receiving timely treatment, and patients who initiated
treatment 46 weeks after surgery as receiving delayed treatment.
In addition, we categorised patients by 4-week intervals to
determine the potential benefit of early initiation of treatment.
Early termination of treatment
Only women who initiated chemotherapy within 12 weeks after
surgery were included in the analysis of early termination of
therapy. Treatment duration was defined as the number of days
between the first and last claim for chemotherapy. Subjects were
categorised as receiving treatment for p3 months or 3–7 months.
Treatment
We used the International Classification of Diseases, 9th revision,
Clinical Modification (ICD-9-CM) codes and AMA Current
Procedural Terminology Codes (CPT) to categorise surgical
procedures for OC. Among patients who underwent OC-directed
surgery, we identified patients who received any cytotoxic
chemotherapy in a physician’s office or in an outpatient hospital
unit.
Socioeconomic status
An aggregate socioeconomic status (SES) score was generated from
a hierarchy of income data from the 2000 Census, according to the
method adapted from Nancy Krieger (Bach et al, 1999). Patients
were ranked on a 1–5 scale, with 1 as the lowest value, based on a
formula that incorporated as many of the following variables as
were available: median income in the census tract of residence,
median income in the zip code of residence, census tract per capita
income, zip code per capita income. Patients for whom all values
were missing were assigned to the lowest SES category.
Comorbid disease
To assess the prevalence of comorbid disease in our cohort, we
used the Charlson comorbidity index as adapted by Klabunde et al
(Deyo et al, 1992; Klabunde et al, 2000, 2002). Medicare inpatient
and outpatient claims were searched for ICD-9-CM diagnostic
codes that indicated a history of myocardial infarction, congestive
heart failure, peripheral vascular disease, cerebrovascular disease,
dementia, chronic pulmonary disease, connective tissue disease,
mild-to-severe liver disease, diabetes with or without end-organ
damage, hemiplegia, moderate-to-severe renal disease, or acquired
immunodeficiency syndrome in the Medicare files from 12 months
before to 1 month after the diagnosis of cancer. Each condition was
weighted, and patients were assigned a score based on the
Klabunde–Charlson index (Klabunde et al, 2000, 2002).
Survival
Survival was calculated as the number of months from the cancer
diagnosis date to the Medicare date of death. Ovarian-cancer-
specific survival was defined as the number of months from the
cancer diagnosis to date of death from OC. Patients who survived
past the end of follow-up (31 December 2003) were censored and
contributed the time from their diagnosis date to the end of follow-
up to the analyses of overall survival.
Statistical analysis
The w
2 test was used to compare the frequency distributions of
categorical variables. All hypothesis tests were two-sided. In a
logistic regression analysis, we modelled the predictors of delayed
treatment. In Cox proportional hazards analyses, we modelled the
overall mortality hazard ratios (HRs) of patients who received
delayed treatment compared to other patients, controlling for the
other predictor variables. We also generated adjusted Kaplan–
Meier curves of overall survival by delayed vs timely start of
chemotherapy and for termination in p3 vs 43 months.
RESULTS
We identified 6047 individuals with stages III–IV epithelial OC
from the SEER-Medicare database. A total of 3585 women
underwent OC-directed surgery. Among these women, 2558
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s(71%) received at least one cycle of chemotherapy. Table 1 shows
their demographic characteristics.
Treatment delay
Among the 2558 patients who received chemotherapy, 1712 (67%)
began treatment within 6 weeks of surgery, while 846 (33%)
initiated chemotherapy 46 weeks after surgery. The median time
to the initiation of chemotherapy was 5 weeks after surgery. In
univariate analysis, advanced age, black race, being unmarried and
an increased number of comorbid conditions were associated with
delayed treatment; living in a metropolitan area, treatment at a
teaching hospital, advanced stage, histology, SES and year of
diagnosis were not associated with delayed treatment (Table 1). In
a logistic regression model, advanced age, black race and marital
status were associated with delayed initiation of chemotherapy
(Table 2). Black patients were more than twice as likely as white
patients to delay initiation of chemotherapy (P¼0.0007).
In a Cox proportional hazards regression model, treatment delay
was associated with a 13% increase in overall mortality (HR¼1.13;
95% CI, 1.03–1.25) (Table 2). Advanced age at diagnosis, stage IV
disease, mucinous histology and increasing medical comorbidities
were also associated with an increased risk of death. Treatment at a
teaching hospital was associated with a lower mortality.
Table 2 Association of demographic and clinical characteristics with
initiation of chemotherapy 46 weeks after surgery and overall mortality
hazard ratios in patients with ovarian cancer by time to initiation of
chemotherapy
46 weeks to initiation of treatmentOverall mortality
Odds ratio* (95% CI)
Hazard ratio
(95% CI)*
Initiation of treatment
p6 weeks — Referent
46 weeks — 1.13 (1.03–1.25)*
Age at diagnosis
65–70 Referent Referent
70–74 1.02 (0.81–1.27) 1.23 (1.09–1.38)
*
75–79 1.31 (1.04–1.65)* 1.27 (1.12–1.44)
*
80+ 1.47 (1.11–1.93) 1.45 (1.24–1.68)
*
Race
White Referent Referent
Black 2.24 (1.42–3.52)
* 0.80 (0.62–1.05)
Other 1.38 (0.94–2.03) 0.82 (0.66–1.03)
Stage
III Referent Referent
IV 0.95 (0.80–1.1) 1.22 (1.12–1.34)
*
Histology
Serous Referent Referent
Mucinous 1.37 (0.89–2.09) 1.42 (1.13–1.78)
*
Endometrioid 0.80 (0.58–1.11) 0.91 (0.77–1.08)
Other 1.17 (0.96–1.42) 1.08 (0.97–1.20)
Live in a metropolitan area
Yes Referent Referent
No 0.89 (0.65–1.24) 1.1 (0.9–1.3)
No. of comorbid conditions
0 Referent Referent
1 1.13 (0.92–1.37) 1.08 (0.97–1.20)
X2 1.23 (0.99–1.52)
* 1.31 (1.17–1.47)
*
SES
Lowest quintile Referent Referent
Second quintile 1.12 (0.85–1.48) 1.01 (0.87–1.18)
Third quintile 1.13 (0.85–1.49) 1.03 (0.89–1.20)
Fourth quintile 1.19 (0.89–1.58) 0.93 (0.79–1.08)
Fifth quintile 1.09 (0.82–1.44) 0.91 (0.79–1.06)
Marital status
Yes Referent Referent
No 1.19 (1.00–1.42)
* 1.03 (0.94–1.13)
Unknown 1.31 (0.78–2.19) 0.96 (0.72–1.28)
Teaching hospital
No Referent Referent
Yes 0.88 (0.71–1.09) 0.82 (0.73–0.92)
*
All variables controlled for each other, and year of diagnosis. *Po0.01.
Table 1 Univariate associations between weeks to initiation of
chemotherapy and demographic and clinical variables
p6 6 Total
Months to chemotherapy N % N % N % P-value
1712 (67) 846 (33) 2558 (100)
Age at diagnosis
65–69 475 (28) 203 (24) 678 (27)
70–74 593 (35) 259 (31) 852 (33)
75–79 429 (25) 242 (29) 671 (26)
80+ 215 (13) 142 (17) 357 (14) 0.0002
Race
White 1598 (94) 756 (89) 2354 (92)
Black 42 (2) 44 (5) 86 (3)
Other 72 (4) 46 (5) 118 (5) 0.0004
Live in metropolitan location
No 159 (9) 67 (8) 226 (9)
Yes 1553 (91) 779 (92) 2332 (91) 0.25
Marital status
No 752 (44) 426 (50) 1178 (46)
Yes 916 (54) 395 (47) 1311 (51)
Unknown 44 (3) 25 (3) 69 (3) 0.005
Teaching hospital
No 302 (18) 166 (20) 468 (18)
Yes 1410 (82) 680 (80) 2090 (82) 0.22
Histology
Serous 1066 (62) 508 (60) 1574 (62)
Mucinous 58 (3) 40 (5) 98 (4)
Endometrioid 150 (9) 59 (7) 209 (8)
Other 438 (26) 239 (28) 677 (26) 0.077
Stage
III 1065 (62) 530 (63) 1595 (62)
IV 647 (38) 316 (37) 963 (38) 0.83
No. of comorbid conditions
0 894 (52) 403 (48) 1297 (51)
1 475 (28) 241 (28) 716 (28)
X2 343 (20) 202 (24) 545 (21) 0.03
SES
Lowest quintile 318 (19) 156 (18) 474 (19)
Second quintile 324 (19) 161 (19) 485 (19)
Third quintile 343 (20) 172 (20) 515 (20)
Fourth quintile 338 (20) 174 (21) 512 (20)
Fifth quintile 389 (23) 183 (22) 572 (22) 0.97
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sThe median survival for women who initiated treatment within 6
weeks was 34 months compared to 28 months for patients who
began therapy more than 6 weeks after surgery. Kaplan–Meier
analysis demonstrated that women who initiated treatment 46
weeks after had poorer overall (Po0.0001) and OC-specific
(P¼0.009) survival than women who did not delay treatment
(Figure 1). However, initiating therapy o4 weeks postoperatively
provided no survival benefit from doing so at 4–8 weeks
(P¼0.27).
Early termination of treatment
Among the 1932 patients who initiated therapy within 12 weeks
after surgery (Table 3), the median duration of therapy was 3.5
months or B15 weeks, consistent with our assumption that if
standard treatment with six cycles were administered every 3
weeks, it would take about 15 weeks from initiation to completion
of therapy. A total of 714 patients (37%) were treated for p3
months and 1218 (63%) for 3–7 months. In univariate analysis,
race, type of hospital and number of medical comorbidities were
associated with duration of treatment (Table 3). In a logistic
regression model treatment at a teaching hospital was associated
with receiving 3–7 months of therapy (Table 4).
In a Cox proportional hazards regression model, patients treated
for 3–7 months had 16% lower mortality than patients treated for
p3 months (HR¼0.84; 95% CI, 0.75–0.94) (Table 4). The median
survival was 38 months for those treated for 3–7 months
compared to 33 months for women treated for o3 months.
Figure 2 displays the Kaplan–Meier plots of survival as a function
of treatment duration. Treatment for p3 months was associated
with poorer overall (Po0.0001) and cancer-specific (Po0.0001)
survival than longer treatment.
DISCUSSION
Our findings demonstrate that among women with advanced OC
who receive chemotherapy, substantial variability exists in the
delivery of this treatment. Women who initiated therapy more
than 6 weeks after surgery and patients who received an
abbreviated course of treatment for less than 3 months were more
likely to die even after adjustment for other known prognostic
factors. Although waiting longer than 6 weeks to initiate therapy
was associated with poorer survival, starting within 4 weeks after
surgery was not associated with better survival.
The timing of initiation of adjuvant chemotherapy and survival
has been studied in a variety of settings, with varied results.
Among patients with lymph node-positive, oestrogen receptor-
negative breast tumours, initiation of chemotherapy within 4
weeks was associated with improved survival (Colleoni et al, 2000).
Elderly patients with early-stage breast cancer appeared to derive
no benefit from early initiation of chemotherapy, but long
treatment initiation delays were associated with increased
mortality (Hershman et al, 2006b). Other adjuvant breast cancer
trials have also failed to detect a benefit from early initiation of
therapy (Shannon et al, 2003; Cold et al, 2005). Our group recently
reported the effect of treatment delay in patients with stage III
colon cancer. In a multivariate analysis, delaying initiation of
treatment for over 3 months was associated with a 50% increase in
colon cancer-specific mortality (Hershman et al, 2006a).
A theoretical basis for early administration of cytotoxic agents
has been demonstrated in several preclinical models. In a
mouse mammary tumour model, removal of the primary lesions
resulted in increased tumour proliferation and, therefore, more
Table 3 Univariate association between length of chemotherapy
treatment (months) and demographic and clinical variables
p3 months 3–7 months Total
Months of chemotherapy N % N % N % P-value
714 (37) 1218 (63) 1932 (100)
Age at diagnosis
65–69 202 (28) 325 (27) 527 (27)
70–74 218 (31) 428 (35) 646 (33)
75–79 190 (27) 309 (25) 499 (26)
80+ 104 (15) 156 (13) 260 (13) 0.20
Race
White 648 (91) 1141 (94) 1789 (93)
Black 29 (4) 26 (2) 55 (3)
Other 37 (5) 51 (4) 88 (5) 0.03
Live in metropolitan location
No 50 (7) 112 (9) 162 (8)
Yes 664 (93) 1106 (91) 1770 (92) 0.09
Marital status
No 341 (48) 531 (44) 872 (45)
Yes 350 (49) 652 (54) 1002 (52)
Unknown 23 (3) 35 (3) 58 (3) 0.16
Teaching hospital
No 106 (15) 229 (19) 335 (17)
Yes 608 (85) 989 (81) 1597 (83) 0.03
Histology
Serous 449 (63) 776 (64) 1225 (63)
Mucinous 13 (2) 35 (3) 48 (2)
Endometrioid 60 (8) 97 (8) 157 (8)
Other 192 (27) 310 (25) 502 (26) 0.47
Stage
III 447 (63) 775 (64) 1222 (63)
IV 267 (37) 443 (36) 710 (37) 0.65
No. of comorbid conditions
0 357 (50) 646 (53) 1003 (52)
1 198 (28) 362 (30) 560 (29)
X2 159 (22) 210 (17) 369 (19) 0.02
SES
Lowest quintile 131 (18) 208 (17) 339 (18)
Second quintile 137 (19) 231 (19) 368 (19)
Third quintile 154 (22) 239 (20) 393 (20)
Fourth quintile 153 (21) 246 (20) 399 (21)
Fifth quintile 139 (19) 294 (24) 433 (22) 0.20
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Figure 1 Kaplan–Meier curve for duration interval from surgery to
initiation of therapy.
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ssusceptibility to cytotoxic chemotherapeutic agents. In these
studies, early perioperative initiation of chemotherapy resulted
in better tumour control than delayed therapy (Fisher et al, 1983;
Bell et al, 1988).
A prospective GOG trial of adjuvant cisplatin and cyclopho-
sphamide with or without doxorubicin examined the effect of delay
in the initiation of treatment and outcome for 349 patients with
stage III OC. The investigators categorised patients by week of
initiation and found that women who began therapy at week 6 had
worse survival than those treated earlier (Omura et al, 1989). In a
multicentre retrospective Italian report as well as a single
institution study from the United States, timing to initiation of
treatment had no effect on survival (Gadducci et al, 2005; Aletti
et al, 2007). In a separate study of 472 patients, Flynn et al (2002)
found that women who started chemotherapy within 3 weeks after
surgery had a shorter progression-free interval than women who
started later. However, the early treatment group had a signi-
ficantly higher percentage of patients with large volume residual
tumours.
Our study differs from previous reports in several respects. We
compared patients who initiated treatment 6 weeks or earlier after
surgery with women who began treatment later. The majority of
previous studies divided patients by much shorter time intervals.
Patients in the GOG trial were all treated within 6 weeks and
stratified by weekly intervals (Omura et al, 1989). Similarly, the
majority of patients in the other reports were treated relatively
early (Flynn et al, 2002; Gadducci et al, 2005; Aletti et al, 2007).
Aletti et al (2007) and the Multicenter Italian Study Group divided
patients into quartiles, the last quartile consisting of patients
treated 434 days after surgery (Omura et al, 1989; Gadducci et al,
2005). These data suggest that very early treatment may be of
limited clinical benefit but that prolonged delays in treatment
initiation may have a deleterious effect on survival. Half of our
elderly subjects were treated 5 weeks or more after surgery. The
relative contributions of patient and physician preferences,
performance status and duration of recovery from surgery to
delay are unknown.
We found that women treated with chemotherapy for a total
duration of o3 months had a 16% higher risk of dying than
women treated longer. Similar findings have been reported in both
adjuvant colon cancer and breast cancer treatment (Tingulstad
et al, 2003; Hershman et al, 2005). Previous reports have
found that patients treated at teaching hospitals were more likely
than those at non-teaching hospitals to receive a full six cycles of
therapy (Tingulstad et al, 2003; Paulsen et al, 2006b). In a patterns
of care study, Paulsen et al (2006b) demonstrated that 43% of
patients at non-teaching hospitals but only 16% of patients at
teaching hospitals received o6 courses of therapy. Notably, only
72% of women at non-teaching hospitals received some form of
chemotherapy. In our cohort, 32% of patients at non-teaching
hospitals compared to 38% at teaching hospitals received o3
months of therapy. While statistically significant, the difference
was quite small.
This study is one of the first to examine age and racial
differences in the quality of chemotherapy delivery in women with
OC. Advancing age was associated with a progressively greater risk
Table 4 Association of demographic and clinical characteristics with
duration of chemotherapy p3 months and mortality hazard ratios in
patients with ovarian cancer by duration of chemotherapy
p3 months treatment Overall mortality
Odds ratio* (95% CI) Hazard ratio (95% CI)*
Length of treatment
o3 months — Referent
3–7 months — 0.84 (0.75–0.94)
*
Age at diagnosis
65–70 Referent Referent
70–74 1.23 (0.96–1.57) 1.29 (1.12–1.48)*
75–79 1.02 (0.79–1.32) 1.29 (1.11–1.49)*
80+ 0.96 (0.70–1.32) 1.49 (1.25–1.79)*
Race
White Referent Referent
Black 0.60 (0.34–1.05) 0.83 (0.59–1.17)
Hispanic 2.30 (0.72–7.28) 1.24 (0.65–2.36)
Other 0.69 (0.43–1.13) 0.89 (0.66–1.20)
Stage
III Referent Referent
IV 0.97 (0.80–1.18) 1.26 (1.13–1.40)
*
Histology
Serous Referent Referent
Mucinous 1.71 (0.89–3.32) 0.95 (0.67–1.44)
Endometrioid 0.95 (0.67–1.35) 0.80 (0.65–0.98)
Other 0.92 (0.74–1.14) 1.01 (0.89–1.15)
Live in a metropolitan area
Yes Referent Referent
No 1.40 (0.96–2.04) 1.07 (0.86–1.32)
No. of comorbid conditions
0 Referent Referent
1 1.05 (0.84–1.30) 1.12 (0.99–1.27)
X2 0.78 (0.61–1.00) 1.19 (1.03–1.36)
*
SES
Lowest quintile Referent Referent
Second quintile 1.08 (0.79–1.47) 1.04 (0.87–1.24)
Third quintile 1.02 (0.74–1.40) 1.17 (0.98–1.40)
Fourth quintile 1.05 (0.76–1.44) 0.94 (0.78–1.13)
Fifth quintile 1.36 (0.99–1.87) 0.93 (0.77–1.11)
Marital status
Yes Referent Referent
No 0.88 (0.73–1.07) 1.10 (0.98–1.22)
Unknown 0.83 (0.48–1.43) 1.12 (0.81–1.55)
Teaching hospital
No Referent Referent
Yes 0.75 (0.58–0.97) 0.83 (0.73–0.96)*
All variables controlled for each other and year of diagnosis. *Po0.01.
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Figure 2 Kaplan–Meier curve for duration chemotherapy.
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sof delay in initiation of chemotherapy. Previous work has
suggested that elderly OC patients are less likely to receive
chemotherapy than younger patients and that those who do are
often treated with less-aggressive regimens (Bruchim et al, 2002;
Efstathiou et al, 2007). A recent study of breast cancer patients
suggested that black patients and elderly patients were more likely
to receive nonstandard treatment regimen (Griggs et al, 2007).
Similarly, in our series, black patients were more likely to
experience a delay in starting chemotherapy. Previous univariate
analysis of SEER data suggested that black patients were less likely
to receive guideline-based chemotherapy (Harlan et al, 2003).
Treatment quality is influenced by physician-related factors.
Several studies have demonstrated superior outcomes for women
treated by surgical specialists and high-volume surgeons (Junor
et al, 1999; Carney et al, 2002; Elit et al, 2002; Earle et al, 2006; Goff
et al, 2006, 2007; Paulsen et al, 2006b; Vernooij et al, 2007). In an
analysis of over 3000 patients, those operated on by gynaecologic
oncologists were more likely to undergo surgical cytoreduction
and had improved outcomes (Earle et al, 2006). Likewise, patients
who were operated on at high-volume facilities and teaching
hospitals are more likely to undergo comprehensive surgical
staging and cytoreduction, and have better survival than those
treated at smaller and non-teaching hospitals (Tingulstad et al,
2003; Paulsen et al, 2006b; Vernooij et al, 2007). However, many
patients with OC do not receive care from surgical specialists or at
large volume facilities (Carney et al, 2002; Bristow et al, 2004).
Although the patients in the SEER-Medicare database are
representative of elderly patients treated in the United States, the
database has a number of limitations. It does not include patients
under the age of 65 years. It does not include data on important
prognostic factors, such as the volume of residual tumour at the
initiation of chemotherapy; the actual doses delivered (we used
duration of therapy as a surrogate for dose intensity); patient and
physician preferences, which are critically important to both the
initiation and continuation of chemotherapy; and performance
status. Although we used age and medical comorbidities as
surrogates, these variables are unable to compensate fully for the
lack of performance status information.
Our findings indicate that delayed treatment initiation and early
chemotherapy discontinuation were common in elderly women
with OC, and that these variations in treatment delivery are
associated with survival. Although early initiation of chemotherapy
appears to confer little benefit, prolonged delays in beginning
treatment and early discontinuation of treatment are associated
with poor outcomes. Prospective studies of factors that influence
the quality of care in women with OC are needed, but until such
studies are completed, efforts should be made to facilitate prompt
initiation and full completion of adjuvant chemotherapy.
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